Breast myofibroblastoma is a rare benign tumor made of fibrous and muscle-like cells in the breast. It usually grows slowly and does not spread, and many people have no symptoms besides a painless lump. Most cases are found in adults, more often in men and postmenopausal women, but it can occur in others. Treatment is usually simple surgical removal, and the outlook is excellent with very low risk of return. Knowing more about breast myofibroblastoma can make it easier to decide on imaging and follow-up with your care team.
Overview
Breast myofibroblastomaSymptoms
Breast myofibroblastoma usually causes a painless, slow-growing, firm lump that feels smooth and movable. Many notice no other symptoms—no nipple discharge, skin changes, or underarm swelling. It’s often found incidentally on imaging or during a routine exam.
Outlook and prognosis
Most people with breast myofibroblastoma do well. It’s a slow-growing, noncancerous tumor, and surgery usually removes it completely with a low chance of coming back. Follow-up visits and imaging help confirm healing and watch for rare recurrences.
Causes and risk factors
Breast myofibroblastoma has no known environmental or lifestyle cause. It usually arises in older adults—more often in men and postmenopausal women—and sometimes alongside gynecomastia or hormone therapy. Many tumors show a somatic 13q14 chromosomal deletion; this change isn’t inherited.
Genetic influences
Genetics plays a limited role in breast myofibroblastoma. Most cases are sporadic, though many tumors show a benign deletion involving 13q14 affecting the RB1 region. These changes arise in the tumor cells themselves and aren’t typically inherited.
Diagnosis
Doctors suspect breast myofibroblastoma from a breast exam and imaging, but the diagnosis of breast myofibroblastoma is confirmed by a core needle biopsy. A pathologist checks the tissue under a microscope and uses markers to rule out cancer.
Treatment and drugs
Treatment for breast myofibroblastoma usually involves a small surgical removal of the lump, aiming to keep healthy breast tissue intact. Doctors often confirm the diagnosis with a core needle biopsy before surgery. Follow‑up visits and imaging check for rare regrowth and reassure healing.
Symptoms
Many people with Breast myofibroblastoma notice a slow-growing, painless breast lump that feels firm and movable. Symptoms vary from person to person and can change over time. Early symptoms of Breast myofibroblastoma are often minimal, and some people have no discomfort at all until a routine exam or scan brings it to attention.
A firm, smooth lump in the breast usually doesn’t hurt. It often feels mobile under the skin and may be easy to move with your fingers. Many notice it while showering or getting dressed.
The lump tends to enlarge gradually over weeks to months. Sudden growth is uncommon.
One side may look or feel fuller where the lump sits. Bras or tops may fit differently on that side.
Some people have a dull ache or tenderness if the lump presses on nearby tissue. Pain is usually mild and comes and goes.
How people usually first notice Breast myofibroblastoma?
Many people first notice breast myofibroblastoma as a painless, slow-growing lump in the breast or chest wall, often found by chance in the shower or during a routine exam. It tends to feel well-defined and movable under the skin, and there are usually no skin changes, nipple discharge, or underarm swelling. Most cases are picked up when a clinician feels a firm nodule on exam or when a screening mammogram or ultrasound flags a new mass, leading to a needle biopsy that confirms this benign (noncancerous) tumor.
Types of Breast myofibroblastoma
Breast myofibroblastoma is a rare, usually benign tumor of the breast stroma that can look and feel different from person to person. Symptoms don’t always look the same for everyone. Some people notice a slow-growing, painless lump found on routine exam or imaging, while others feel a firmer, mobile mass that prompts a visit. Clinicians often describe them in these categories to capture patterns that help with diagnosis and to explain the known types of breast myofibroblastoma.
Classic type
This is the most common form, with well-circumscribed, firm nodules composed mainly of spindle-shaped cells and collagen. It often presents as a slow-growing, painless breast lump found on exam or imaging.
Cellular variant
This type has more densely packed spindle cells and less collagen, which can make it look more active on imaging. People with this variant may notice a firmer lump, but it still behaves benignly in most cases.
Collagenized variant
Thick bands of collagen dominate, sometimes making the tumor feel quite firm or rubbery. Imaging may show a very well-defined mass that grows slowly over time.
Myxoid variant
This variant has more gelatinous (myxoid) stroma, which can make the mass feel softer and appear brighter on certain scans. It generally remains well circumscribed and benign in behavior.
Epithelioid variant
Cells look more rounded or epithelioid rather than spindle-shaped, which can mimic other tumors on biopsy. Careful pathology review confirms the benign nature in most cases.
Lipomatous variant
Fat is intermixed with the tumor, sometimes making it feel softer and causing a mixed appearance on imaging. This can resemble a lipoma but has the characteristic myofibroblastic features.
Infiltrative border
This pattern shows irregular edges that blend into nearby tissue on microscopy, which can raise concern for other conditions. Despite the look, clinical behavior tends to remain indolent after complete removal.
Atypical features
Some tumors show mild nuclear atypia or unusual cell shapes that can alarm on first glance. Pathology still supports a benign diagnosis when other reassuring features are present.
Gynecomastia-associated
Seen in some men alongside gynecomastia, where hormonal milieu may be a factor. The lump is typically small to moderate in size and discovered during evaluation for breast enlargement.
Ancient change
Long-standing tumors can develop degenerative changes like calcifications or hyalinization. These changes can alter imaging appearance but do not usually change the benign course.
Desmin-positive subtype
Many myofibroblastomas stain for desmin on pathology, aiding diagnosis when the appearance overlaps with other spindle-cell tumors. This marker helps distinguish types of breast myofibroblastoma from look-alike lesions.
CD34-predominant
Strong CD34 staining is common and can be the dominant feature in some cases, helping exclude other entities. This immunoprofile supports the diagnosis alongside the clinical and imaging picture.
What genetics can tell you about symptoms
Certain genetic changes, especially deletions involving the 13q14 region that affect the RB1 pathway, are common in breast myofibroblastoma and help explain its slow-growing, painless lump. These changes drive benign overgrowth of myofibroblasts, leading to a firm, well-circumscribed mass.
Causes and risk factors
The exact cause of breast myofibroblastoma is not clear. It is more common in older men and postmenopausal women, and risk factors for breast myofibroblastoma may include hormone shifts from gynecomastia or past antiandrogen therapy. Some tumors show a small missing piece on chromosome 13 in the RB1 area, and this change happens in the tumor cells and is not inherited. There are no proven links to family history of breast cancer, and lifestyle or environmental triggers like diet, alcohol, smoking, or breast injury have not been shown to raise risk. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Environmental and biological risk factors
Breast myofibroblastoma is a rare, benign breast tumor, and known risk factors for breast myofibroblastoma are limited. Doctors often group risks into internal (biological) and external (environmental). Current evidence points more to biology—especially age and hormonal state—while specific environmental triggers have not been confirmed.
Breast myofibroblastoma occurs most often in adults in their 50s to 70s. Age-related changes in breast tissue and hormones likely make the supporting tissue more susceptible. It can still appear in younger adults, but this is uncommon.
Cases are more frequent in men and in women after menopause. Natural declines in sex hormones appear to change the breast’s supporting tissue in ways that favor these benign growths.
Shifts in estrogen or androgen levels can affect how the breast’s supporting tissue grows and repairs. This altered signaling may nudge these cells toward forming a benign mass, though the overall risk remains low.
Gynecomastia reflects a hormone imbalance in the breast. Its link to this tumor remains uncertain, and most men with gynecomastia will never develop it.
Genetic risk factors
Breast myofibroblastoma is a rare, noncancerous breast stromal tumor whose key genetic changes usually happen inside the tumor cells rather than being inherited. Risk is not destiny—it varies widely between individuals. In most cases, tumor testing shows loss of a small stretch on chromosome 13 (the 13q14 region) that includes the RB1 gene, which helps regulate cell growth. There are no early symptoms of breast myofibroblastoma that point to a family-passed risk.
13q14 deletion: In many tumors, a chunk of DNA on chromosome 13q14 is missing. This region contains RB1, and its loss weakens normal growth control. Lab testing can detect this deletion in the tumor.
RB1 gene loss: RB1 acts like a brake that keeps cells from dividing too fast. Losing one copy in tumor cells is a common driver in breast myofibroblastoma. Many tumors show absent RB protein on specialized staining.
Somatic, not inherited: The genetic changes occur after conception and are limited to the tumor. They are not typically present in blood or passed down through families. Routine germline genetic testing is generally not needed.
No known predisposition: There is no well-established inherited syndrome that clearly raises the chance of breast myofibroblastoma. Even in families with other cancers, this tumor is usually a sporadic event. Doctors rarely recommend family screening for this condition.
Shared genetic pattern: This tumor shares the 13q14 loss seen in spindle cell lipoma and cellular angiofibroma. The overlap points to a common pathway rather than a unique hereditary risk. Recognizing this helps confirm the diagnosis.
Lifestyle risk factors
Breast myofibroblastoma is rare, and there are no well-established lifestyle risk factors for its development. Current research has not identified diet, exercise, alcohol, tobacco, or stress as drivers of risk. Most advice focuses on overall wellbeing and ease of care rather than altering disease risk. In short, evidence for lifestyle risk factors for breast myofibroblastoma is limited.
There is no known dietary pattern that increases or decreases the risk of breast myofibroblastoma. Specific foods or nutrients have not been shown to influence its development.
No evidence links activity levels with the risk of developing this tumor. Staying active may still support overall health and recovery if treatment is needed.
These habits have not been shown to specifically change the risk of breast myofibroblastoma. Limiting alcohol and avoiding smoking remain beneficial for general health.
Obesity has not been linked to a higher risk of this benign tumor. Maintaining a healthy weight may make imaging and potential surgical care easier.
Risk prevention
Breast myofibroblastoma is rare and benign, and there’s no proven way to prevent it outright. Practical steps focus on noticing changes early and getting timely evaluation so any lump is properly checked. Screenings and check-ups are part of prevention too.
Get familiar with how your breasts normally look and feel so changes stand out. Noticing early symptoms of breast myofibroblastoma—often a new, firm, usually painless lump—can prompt timely care. Most breast lumps are not cancer, but they still deserve evaluation.
If you find a new lump that persists for a few weeks, arrange a clinical exam and appropriate imaging. Early assessment helps confirm whether it’s a benign tumor like breast myofibroblastoma or something else. Don’t wait for pain to appear.
Ask about breast exams during routine visits, especially if you’re postmenopausal or an older man. A clinician can spot features you might miss at home. They can also guide when imaging is needed.
Go over hormones, supplements, and anabolic steroid use with your clinician. Avoid unsupervised hormone products, which can affect breast tissue. This helps lower contributors to benign growths such as breast myofibroblastoma.
Transmission
Breast myofibroblastoma is not contagious and cannot be transferred from one person to another. It develops when certain connective tissue cells in the breast grow into a benign lump on their own, a sporadic process not linked to infection or exposure. There is no known genetic transmission of breast myofibroblastoma; it is not typically inherited, so family members don’t face increased risk just because one relative has it. Everyday contact, including hugging or sharing a home, does not spread breast myofibroblastoma.
When to test your genes
Consider genetic testing if you have multiple or recurrent breast myofibroblastomas, unusually early onset, tumors in different body sites, or a strong family history of soft-tissue tumors or multiple cancers. Testing often focuses on tumor genetics (e.g., 13q/RB1 loss) and, when patterns suggest inheritance, germline panels. Discuss with a genetics professional to tailor care.
Diagnosis
For many, the first step comes when everyday activities start feeling harder, like noticing a new, firm breast lump in the shower or during a routine exam. Breast myofibroblastoma is usually found as a slow-growing, painless mass, and imaging alone can’t label it with certainty. Many people find reassurance in knowing what their tests can—and can’t—show. The diagnosis of breast myofibroblastoma is confirmed by taking a tissue sample and reviewing it under the microscope with special stains.
Your clinician checks the size, feel, and mobility of the lump and looks for skin or nipple changes. These features help decide which tests come next.
Imaging looks for a smooth, well-defined solid mass without worrisome calcifications. These tests suggest a benign pattern but cannot confirm the exact type.
MRI may be used if findings are unclear or the lump is hard to see on other imaging. It shows detail about the mass and surrounding tissue to guide biopsy planning.
A small tissue sample is taken with a needle under imaging guidance. This sample is essential for how breast myofibroblastoma is diagnosed.
Stages of Breast myofibroblastoma
Breast myofibroblastoma does not have defined progression stages. It is a benign breast tumor that typically grows slowly, does not spread to other parts of the body, and for many people stays the same size or causes few issues over time—early symptoms of breast myofibroblastoma may be minimal, such as a small, painless lump. Different tests may be suggested to help confirm the diagnosis and rule out other breast lumps, often including a physical exam, imaging like ultrasound or mammogram, and a core needle biopsy to look at the tissue.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, especially after hearing a diagnosis of breast myofibroblastoma. The short answer is that the outlook is excellent. This is a benign (noncancerous) tumor that grows slowly, and once it’s removed with surgery, it very rarely comes back. Most people return to regular activities quickly, and there is no proven increase in the risk of breast cancer because of breast myofibroblastoma itself.
Doctors call this the prognosis—a medical word for likely outcomes. Recurrence rates are low when the tumor is fully excised, and even if a small rim of tissue is left behind, regrowth is uncommon and usually manageable with another minor surgery. Death from breast myofibroblastoma has not been reported in the medical literature, so discussions about mortality do not apply the way they do for malignant tumors. For many, follow‑up consists of routine clinical exams and, when recommended, standard breast imaging on the usual schedule.
Knowing what to expect can ease some of the worry. Early symptoms of breast myofibroblastoma are often just a painless, firm lump noticed in the breast or chest area, and many are found incidentally on imaging done for other reasons. After treatment, lingering tenderness or tightness in the area typically fades over weeks to months. Talk with your doctor about what your personal outlook might look like, including whether any additional monitoring is needed based on the size and location of your tumor and your overall health.
Long-term effects
Breast myofibroblastoma has an excellent long-term outlook because it is benign. Long-term effects vary widely, but most people do well after simple removal of the lump. It does not spread to other parts of the body, and recurrences are uncommon when the mass is fully excised. Early symptoms of breast myofibroblastoma are often mild or absent, so long-term care usually centers on routine check-ins rather than intensive treatment.
The risk of the lump coming back in the same spot is low, especially if it was completely removed. If it does recur, another simple surgery usually resolves it.
Breast myofibroblastoma does not metastasize to lymph nodes or distant organs. This means the long-term survival outlook is excellent.
Surgery can leave a small scar and, at times, a slight change in breast or chest shape. These changes are usually mild and fade or soften over months.
Periodic check-ups or imaging may be recommended to confirm stability. Doctors may track these changes over years to see whether any new lumps appear.
How is it to live with Breast myofibroblastoma?
Living with breast myofibroblastoma is usually less about symptoms and more about the uncertainty that comes with finding a new breast lump and needing tests to confirm it’s benign. Most people feel well physically; the main impact is scheduling imaging, a biopsy, and sometimes a brief outpatient surgery, then waiting for results, which can be stressful for you and those close to you. After removal, day-to-day life typically returns to normal with minimal limitations, though follow-up visits may be recommended to check healing and reassure everyone that it hasn’t come back. For many, clear communication with the care team and sharing updates with family or friends helps ease worry and keeps life moving smoothly.
Treatment and drugs
Breast myofibroblastoma is a rare, noncancerous tumor, and treatment focuses on removing the lump and preventing it from coming back. Most people do well with a simple surgical excision (lumpectomy), which fully removes the mass with a small rim of normal tissue; hospital stays are usually short, and recovery is straightforward. If the tumor is very small, slow-growing, and not causing symptoms, some specialists may suggest watchful waiting with periodic imaging, but surgery is the standard approach for a firm diagnosis and cure. Medicines like chemotherapy, radiation, or hormone therapy are not usually needed because breast myofibroblastoma does not behave like cancer. Treatment plans often combine several approaches, but in this condition, follow-up exams and imaging are typically the only ongoing steps after surgery.
Non-drug treatment
Breast myofibroblastoma is a benign breast lump, so treatment focuses on comfort, monitoring, and removing it if it bothers you or changes over time. Many feel fine and only notice a firm, slow-growing lump during a shower or routine check. Non-drug care ranges from surgical removal to simple comfort steps and follow-up imaging. Plans are tailored to the tumor’s size, location, symptoms, and your preferences.
The lump is removed with a small margin of healthy tissue, often as an outpatient procedure. This is usually curative and recurrence is rare.
If a core biopsy confirms a benign lesion and it isn’t bothering you, your team may suggest watchful monitoring with exams and imaging. Early symptoms of breast myofibroblastoma can be a small, painless lump, so any new changes like growth or tenderness should prompt a recheck.
A well-fitted, supportive bra can ease local discomfort or pulling. Soft fabrics and avoiding underwire during tender periods may help.
Warm compresses and brief rest from chest-focused workouts can reduce soreness. Gentle over-the-counter silicone pads can cushion the area under clothing.
Your genes may have an impact on how drugs work for you
Two people can receive the same medicine for breast myofibroblastoma yet respond differently because genes influence how fast the body activates, breaks down, or clears drugs. Genetic differences may guide dose choices and supportive care, helping tailor treatment and limit side effects.
Pharmacological treatments
Breast myofibroblastoma is a benign breast tumor, and medicines don’t shrink or cure it; surgery is usually the main treatment. People may use medication for discomfort, swelling, or pain—especially if a lump is tender or after a biopsy or surgery. Many have no early symptoms of breast myofibroblastoma, but when soreness shows up, simple pain relievers often help. Drugs that target symptoms directly are called symptomatic treatments.
Eases mild to moderate pain without thinning the blood. Often a good first choice for soreness from the lump or after procedures. Avoid exceeding the maximum daily dose and use caution with liver conditions or alcohol use.
Help reduce pain and inflammation around the breast tissue. Take with food and avoid if you have stomach ulcers, kidney problems, or are on blood thinners. Stop and call your clinician if you notice stomach pain or bleeding.
Can target a small tender area with fewer whole‑body side effects. Apply to intact skin only and wash hands after use. Avoid combining with oral NSAIDs unless your clinician advises it.
Sometimes used for a few days after surgery if pain is not controlled with other medicines. Can cause sleepiness, constipation, and nausea, so use the lowest dose for the shortest time. Store securely and dispose of leftovers through a pharmacy take‑back program.
Genetic influences
In breast myofibroblastoma, the genetic changes doctors see are usually limited to the tumor itself, not something you inherit or pass on. Some people wonder if their condition could be “in the genes.” If you’re asking “is breast myofibroblastoma hereditary,” current evidence suggests it is not. Most cases are sporadic, caused by acquired changes that happen as the lump forms. A common finding is a small missing segment on chromosome 13 that affects a growth‑control gene called RB1, which can loosen the normal brakes on cell growth. These changes are identified in the tumor tissue during pathology testing and are not typically present in your blood or shared by relatives. Because of this, having breast myofibroblastoma doesn’t usually increase genetic risk for your family or link to inherited breast cancer genes.
Is Breast myofibroblastoma genetic?
Genetics plays a limited role in breast myofibroblastoma. Most cases are sporadic, though many tumors show a benign deletion involving 13q14 affecting the RB1 region. These changes arise in the tumor cells themselves and aren’t typically inherited.
Pharmacogenetics—how genetics influence drug effects
For most people, treatment of breast myofibroblastoma is a straightforward surgical removal, so there isn’t a standard role for chemotherapy or targeted drugs. Genetic findings can still matter: many tumors show a small missing piece on chromosome 13 (sometimes noted as 13q14), which helps confirm the diagnosis and avoid unnecessary aggressive therapy. Some tumors also test positive for estrogen or progesterone receptors, but because this growth is benign, hormone-blocking medicines aren’t routinely used. This is where pharmacogenetics may play a smaller, practical role around the operation—anesthesia, pain relievers, and antibiotics—because common gene differences can change how quickly you clear certain medicines. Genetic testing can sometimes identify how your body processes medicine, which may help your team choose safer options or adjust doses. In short, genetics influences treatment of breast myofibroblastoma more by strengthening diagnostic confidence than by directing drug therapy, while also supporting personalized, safer care before and after surgery.
Interactions with other conditions
Breast myofibroblastoma is often found while checking on something else in the breast, such as gynecomastia in men or a suspected cyst, because early symptoms of breast myofibroblastoma are usually minimal. It doesn’t raise the risk of breast cancer and doesn’t spread, but it can mimic cancer on a mammogram or ultrasound, especially when other breast changes or prior scarring are present, which may lead to extra tests to be sure. Hormone shifts—like those after menopause or alongside gynecomastia—are commonly seen in people with this tumor, so conditions that change the hormone environment may be part of the same picture rather than a direct cause-and-effect. Some conditions share underlying mechanisms, such as certain benign soft‑tissue tumors that are closely related to myofibroblastoma on a genetic level. When other benign breast conditions are present, breast myofibroblastoma can be harder to tell apart on imaging or exam, but a core needle biopsy usually settles the diagnosis. Overall, breast myofibroblastoma tends to stay local and independent, interacting with other diseases mostly by complicating imaging and evaluation rather than altering overall health.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and neighbors sometimes noticed a firm, slow-growing lump in the chest area of an older adult that didn’t seem to bother them much day to day. A tailor might feel it while measuring a suit, or someone might discover it in the shower. These quiet stories set the stage for what we now recognize as breast myofibroblastoma, a rare, benign (noncancerous) tumor made of fibrous and muscle-like cells.
First described in the medical literature as a distinct entity in the late 1980s, breast myofibroblastoma was initially recognized because pathologists saw a pattern that didn’t fit typical breast cancers or common benign lumps. Before that, many of these growths were likely grouped under broad labels like “fibrous tumors” or “spindle cell lesions.” As medical science evolved, careful microscopic study and special staining techniques helped separate this tumor from look-alikes, reducing unnecessary aggressive treatment.
Over time, descriptions became clearer: it tends to appear in adults—often those assigned male at birth but also in women—usually as a small, mobile mass discovered on exam or imaging. Case reports from Europe and North America first shaped the picture, and later publications from Asia and other regions confirmed that breast myofibroblastoma occurs across populations. These historical steps helped clinicians understand that, despite its unfamiliar name, the condition behaves in a calm, predictable way.
In the 1990s and 2000s, advances in pathology brought genetic clues. Many tumors showed the same harmless chromosomal change seen in related soft-tissue tumors, reinforcing that breast myofibroblastoma belongs to a family of benign growths with overlapping features. This genetic fingerprint supported what doctors were already observing: the tumor grows slowly, doesn’t spread, and is curable with simple surgery when needed.
Once considered rare, now recognized as uncommon but likely underreported, breast myofibroblastoma entered standard references and teaching materials. Radiology descriptions improved as well, outlining typical appearances on mammogram and ultrasound, which helped reduce confusion with cancer. With each decade, the message became steadier: if the diagnosis is confirmed on a core needle biopsy, treatment can be measured—often just removing the lump, with no chemotherapy or radiation.
Understanding this history matters for people living with breast myofibroblastoma today. Knowing how it was separated from more worrisome conditions explains why doctors emphasize precise diagnosis and why the outlook is so reassuring. It also clarifies why a second opinion from a pathologist experienced in soft-tissue and breast lesions can be helpful for uncommon findings.
In recent decades, knowledge has built on a long tradition of observation. The result is practical: clearer diagnostic criteria, simpler care, and confidence that this is a benign condition with an excellent long-term prognosis.